Wang Haitao, Yang Bo, Chi Xiaohua, Cai Lili, Yu Ruili, Zhu Hongli, Tuo Shuai, Zhang Feng, Wang Xuanchi, Yang Yang, Wu Xiaoxiong, Li Songwei, Lu Xuechun
Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China; Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
Clin Ther. 2014 Jul 1;36(7):1104-11. doi: 10.1016/j.clinthera.2014.05.065. Epub 2014 Jun 27.
Elderly acute myelocytic leukemia (AML) patients have limited treatment options because they poorly tolerate standard-dose chemotherapy. The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML.
Decitabine (10 mg) was given on days 1 to 5, and CIK cells on day 14 with 2 to 8 × 10(9) cells per infusion.
The therapeutic regimen resulted in marked hematologic recovery and was associated with better than expected survival in both cases.
Our experience suggests that the combination therapy is safe and effective for elderly patients with myelodysplastic syndrome-transformed AML.
老年急性髓细胞白血病（AML）患者由于对标准剂量化疗耐受性差，治疗选择有限。本文描述了我们对2例骨髓增生异常综合征转化为AML的老年患者采用超低剂量地西他滨联合输注自体细胞因子诱导杀伤（CIK）细胞的经验。
地西他滨（10毫克）在第1至5天给药，CIK细胞在第14天给药，每次输注2至8×10⁹个细胞。
该治疗方案导致显著的血液学恢复，且两例患者的生存期均优于预期。
我们的经验表明，联合治疗对骨髓增生异常综合征转化为AML的老年患者安全有效。
